TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02284542

Intervention type: PROCEDURE
Intervention: Non-Awake
Description: The patient is maintained under general anesthesia for the full duration of the implant. Upon approximate lead positioning, bilateral EMG of myotomes overlapping dermatomal regions of pain are monitored. Stimulation is delivered through the lead by an external pulse generator in order to elicit compound muscle action potentials (CMAPs) in the target regions. Lead placement is targeted to have symmetric CMAPs (i.e. physiologic midline) and adequate coverage of the painful regions as described by Falowski et al.~(Falowski et al., 2011).
Study: NCT03996759

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory diagnostic medicine
Description: Metabolomic profiling and laboratory diagnosis including blood routine examination, liver function, renal function, myocardial enzyme, coagulation, arterial blood gas analysis, C-reactive protein, procalcitonin, B-type natriuretic peptide, myoglobin, lipopolysaccharide, cytokines (TNF-α, IL-1β, IL-6, etc.), immune cell markers (CD3+, CD4+, CD8+, etc.), and stool routine as well as intestinal microecology analysis.
Study: NCT05346497

Intervention type: PROCEDURE
Intervention: Bentall
Description: Bentall procedure: include replacement of both aortic valve and root

Intervention type: PROCEDURE
Intervention: David
Description: David procedure: include replacement of aortic root and aortic valvuloplasty

Intervention type: PROCEDURE
Intervention: ARR
Description: Aortic root reconstruction: reconstruction instead of replacement of aortic root, without surgery of the valve. include sandwich procedure, adventitia invertion procedure, etc.
Study: NCT03468829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171 Dose 1
Description: Oral inhalation of ALX-0171 Dose 1 once daily for a maximum of 14 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171 Dose 2
Description: Oral inhalation of ALX-0171 Dose 2 once daily for a maximum of 14 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral inhalation of Placebo once daily for a maximum of 14 days
Study: NCT05197621

Intervention type: BIOLOGICAL
Intervention: mRNA COVID-19 vaccine (Pfizer or Moderna)
Description: mRNA vaccine received at any time during pregnancy course
Study: NCT03950479

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D and 4D Transperineal Ultrasound
Description: The evaluation of Pelvic Floor Muscles with 3D and 4D transperineal ultrasound using A Voluson E6 system (GE Healthcare, Zipf, Austria) with RAB 8-4-MHz volume transducer for all acquisitions. Measurements will be performed in axial planes. The levator hiatus area (LHA), the antero-posterior (AP) diameter and the left-right (LR) transverse diameter will be analyzed at rest, during pelvic floor contraction and on maximal Valsalva maneuver.
Study: NCT01785420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 90 minute intravenous infusion of saline as placebo
Study: NCT01565720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: oral
Study: NCT03746171

Intervention type: DIAGNOSTIC_TEST
Intervention: Colonic polyp characterization by BLI
Description: All rectosigmoid \<5 mm polyps, regardless of the presence of larger polyps, will be characterized by BLI-assisted optical diagnosis by using BASIC criteria (neoplastic vs. non neoplastic) and will be included in polyp-level assessment.~The polyp characterization will be always performed and recorded without zoom magnification. In patients in which colonoscopy will be performed with endoscopes equipped with zoom magnification, the zoom will be eventually systematically applied and the characterization with zoom will be also recorded. The post-polypectomy surveillance intervals based on BLI will be calculated by using histology estimation performed without zoom for all patients. Only polyps characterized with high confidence will be included in the analysis; the high-confidence characterization rate will be calculated.
Study: NCT02778087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Box Therapy
Description: The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on the mirror reflection of the unaffected arm throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: active range of motion (AROM), functional tasks with objects, and object manipulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Box Therapy
Description: The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on the mirror reflection of the unaffected arm throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: active range of motion (AROM), functional tasks with objects, and object manipulation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Mirror Box Therapy
Description: The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on an opaque mirror throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: AROM, functional tasks with objects, and object manipulation.
Study: NCT04429048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure elastic band (Sea-Band)
Description: The PC6 acupressure was done via Sea-Band in persistent compressive state for 3 minutes per time and three times a day , then at least 5 days in one week for 6 weeks continuously except modern routine standard therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: General elastic band (no bud)
Description: general elastic band was put over bilateral PC6 acupoints
Study: NCT00353665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine (Ebixa)
Description: 10 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riluzole
Description: riluzole 50 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: riluzole
Description: riluzole 50 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04725422

Intervention type: DRUG
Intervention: Methotrexate
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

Intervention type: DRUG
Intervention: Sulfasalazine
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

Intervention type: DRUG
Intervention: Leflunomide
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

Intervention type: DRUG
Intervention: Pamidronate
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

Intervention type: DRUG
Intervention: Zoledronic acid
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

Intervention type: DRUG
Intervention: Etanercept
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

Intervention type: DRUG
Intervention: Adalimumab
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

Intervention type: DRUG
Intervention: Certolizumab
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

Intervention type: DRUG
Intervention: Infliximab
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

Intervention type: DRUG
Intervention: Golimumab
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

Intervention type: DRUG
Intervention: NSAID
Description: first-line treatment
Study: NCT03269604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic antibiotic during five days previous to the procedure
Description: Prophylactic antibiotic during five days previous to the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic antibiotic during three days previous to the procedure
Description: Prophylactic antibiotic during three days previous to the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Only a single dose of Prophylactic antibiotic
Description: This group will receive a single dose of antibiotic 90 ± 20 minutes prior to the start of the surgical procedure (incision)
Study: NCT03442101

Intervention type: DRUG
Intervention: Patients with psychosis will be treated with known antipsychotic medication
Description: Subjects with first episode psychosis will be treated with risperidone, the most frequently used antipsychotic drug (APD) for 32 weeks. The study will follow a rigorous longitudinal design to capture treatment response whereby those without an adequate response after 16 weeks of treatment will be switched to aripiprazole, another APD for 16 weeks. All patients will be scanned four times: at baseline and after 6, 16, and 32 weeks of treatment.
Study: NCT01601860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of non-pharmacological
Description: Other: Non-pharmacological resources~A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~* Walking (with cervical dilation between 4 and 5 cm)~* Alternating stance associated with ENT (cervical dilatation from 6 to 7 cm)~* Shower (with dilation\> 7 cm);
Study: NCT00655655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatalanib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study (Cohort IIA only)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study (Cohorts IIA and IIB)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Correlative study (Cohort IIA only)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging
Description: Correlative study (Cohorts IIA and IIB)
Study: NCT01601860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other: Routine care
Description: Other: Routine care Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
Study: NCT03578315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HGM
Description: To Study the Efficacy and safety of QSRL and PSNYL in the Treatment of target: A nonrandomized, controlled, split-face comparative study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HGM
Description: To Study the Efficacy and safety of QSRL and PSNYL in the Treatment of target: A nonrandomized, controlled, split-face comparative study
Study: NCT01101568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40mg (single dose) on Days 1 and 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 10mg (single dose) on Days 3 and 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1292263
Description: GSK1292263 300mg BID Days 6 to 14.
Study: NCT03648840

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aversive cue
Description: Participants will be exposed to unpleasant pictures and tones during performance of a task to earn alcohol

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aversive cue
Description: Participants will be exposed to unpleasant pictures and tones during performance of a task to earn alcohol

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aversive cue
Description: Participants will be exposed to unpleasant pictures and tones during performance of a task to earn alcohol

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neutral cue
Description: Participants will be exposed to neutral pictures and tones during performance of a task to earn alcohol
Study: NCT03189485

Intervention type: DRUG
Intervention: the radiotracer 18F-AV-1451
Description: Subjects will receive a single IV bolus injection target dose of approximately 370 MBq (10 mCi ± 20%) of 18F-AV-1451 At approximately 75 minutes post dose, scanning will begin. An approximately 30-minute acquisition (six 5 minute intervals) will be performed
Study: NCT03648840

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neutral cue
Description: Participants will be exposed to neutral pictures and tones during performance of a task to earn alcohol

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neutral cue
Description: Participants will be exposed to neutral pictures and tones during performance of a task to earn alcohol
Study: NCT00098072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart Catheterization
Description: Heart Catheterization and collection of samples
Study: NCT02818361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tripterygium gel
Study: NCT01583322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vargatef
Description: 400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.~The maximum time on monotherapy is 2 years.
Study: NCT03924674

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education, clinical decision support tools
Description: Interventions will include:~1. Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~2. Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~3. Tools to promote discussion about timing and necessity of routine lab draws~4. Education and feedback for physicians regarding costs and harms of routine lab testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education, clinical decision support tools
Description: Interventions will include:~1. Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~2. Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~3. Tools to promote discussion about timing and necessity of routine lab draws~4. Education and feedback for physicians regarding costs and harms of routine lab testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education, clinical decision support tools
Description: Interventions will include:~1. Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~2. Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~3. Tools to promote discussion about timing and necessity of routine lab draws~4. Education and feedback for physicians regarding costs and harms of routine lab testing
Study: NCT02818361

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Study: NCT04165343

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: We will order laboratory blood tests as part of this research study and up to 3 tablespoons of blood will be collected for routine clinical and other laboratory tests relevant to the study. If you are able to become pregnant, you will have a urine pregnancy test before you begin the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: We will order laboratory blood tests as part of this research study and up to 3 tablespoons of blood will be collected for routine clinical and other laboratory tests relevant to the study. If you are able to become pregnant, you will have a urine pregnancy test before you begin the study.
Study: NCT00176930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4+/CD25+ cells
Description: On days -2, patients will receive CD4+/CD25+ cells intravenously.
Study: NCT00761176

Intervention type: DEVICE
Group type: OTHER
Intervention: The Provant Therapy System
Description: The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.
Study: NCT02588248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peppermint Oil
Description: During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 640 mg of L-Menthol).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 80 ml of Solution B, also has 0 mg of L-Menthol).
Study: NCT03139955

Intervention type: DEVICE
Intervention: Bodytrak
Description: Bodytrak is a wireless earpiece which can monitor the user's vital signs such as tympanic (ear) temperature and heart rate. The earpiece is non-invasive and should fit comfortably within the right ear, similar to an earphone with an over-the-ear hook. Bodytrak is currently in a prototype stage. For further information please visit http://www.bodytrak.co
Study: NCT04769583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole based quadriple therapy
Description: patient randomized in QC will be treated by a double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), metronidazole (500 mg x 2 per day) and clarithromycin (500 mg x 2 per day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo based quadriple therapy
Description: patient randomized in TT will be treated by double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), clarithromycin (500 mg x 2 per day) and a placebo of metronidazole.
Study: NCT03971461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutathera
Description: administered intravenously every 8 weeks for a total of 4 doses
Study: NCT04290962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Therapy
Description: Complete web-based lifestyle intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04339946

Intervention type: DIAGNOSTIC_TEST
Intervention: Three-dimensional rectal water contrast transvaginal ultrasonography (3D-RWC-TVS)
Description: Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.

Intervention type: DIAGNOSTIC_TEST
Intervention: Two-dimensional rectal water contrast transvaginal ultrasonography (2D-RWC-TVS)
Description: Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution.
Study: NCT04350658

Intervention type: PROCEDURE
Intervention: Transcatheter aortic valve implantation required for symptomatic aortic stenosis
Description: The procedure is performed via transfemoral or transcarotid access; Patients were confirmed to be eligible for TAVR by a multidisciplinary heart team including at least an interventional cardiologist, a cardiothoracic surgeon and an anesthetist. All TAVR implantation procedures were performed with the Edwards SAPIEN 3 THV or the MEDTRONIC CoreValve EVOLUT . For all patients, both vascular access and aortic valve were evaluated before the procedure by multislice computerized tomographic angiography (MSCT) of the entire aorta using vascular windows settings. The prosthesis and the vascular access were left to the discretion of the operating team. Transfemoral access was the first choice when possible. All TAVR procedures were performed in the same hybrid room (in Montpellier University Hospital), Most TAVR were performed under sedation or general anesthesia using mild low profile 14-16 French delivery systems and using percutaneous or surgical vascular access.